GH Therapy and first final height data in Noonan‐like syndrome with loose anagen hair (Mazzanti syndrome). Issue 11 (3rd October 2013)

• Record Type: Journal Article
• Authors: Mazzanti, Laura; Tamburrino, Federica; Scarano, Emanuela; Perri, Annamaria; Vestrucci, Benedetta; Guidetti, Monica; Rossi, Cesare; Tartaglia, Marco
• Is Part Of: American journal of medical genetics. Volume 161:Issue 11(2013:Nov.)
• Page Start: 2756
• Page End: 2761
• Publication Date: 2013-10-03
• Subjects: Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.36255
• Languages: English
• ISSNs: 1552-4825

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="ajmga36255-sec-0001" sec-type="section"> <p>Noonan‐like syndrome with loose anagen hair (NS/LAH or Mazzanti Syndrome) is caused by a single missense mutation in <italic>SHOC2</italic> promoting t<italic>N</italic>‐myristoylation of the encoded protein. Cardinal features include facial features resembling NS, short stature often associated with proven growth hormone deficiency (GHD), typical ectodermal anomalies, and distinctive behavior. Overall, the clinical features are more severe than those generally observed in NS, even though the phenotype improves with age. We report on growth and pubertal trend in seven patients heterozygous for a mutated <italic>SHOC2</italic> allele, treated with long‐term GH‐therapy, and final height (FH) in three of them. They were approximately −3 SDS below the Italian general population standards, they had very low IGF1 levels at baseline and GHD at pharmacological tests. All patients were treated with GH (0.035 mg/kg/day) for a mean period of 8.49 ± 5.72 years. After the 1st year of GH‐therapy, IGF1 level and height velocity had increased. Three of 7 patients reached the FH (−2.34 ± 0.12 SDS) at 18.25 ± 0.73 years, after GH administration for 12.39 ± 2.12 years. Pubertal development was variable, showing a prolonged and delayed puberty or rapid pubertal progression that could impair the FH. Overall, our data in this small cohort suggest that NS/LAH patients benefit from long‐term GH‐therapy, although they do not show the characteristic catch‐up growth of isolated GHD. While the observed growth and pubertal behavior is consistent with a dysfunction of the hypothalamic‐pituitary‐gonadal axis, the functional link between <italic>SHOC2</italic> and the GH/IGF signaling pathways remains to be clarified. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>